Asia-Pacific Liver Cancer Therapeutics Market By Type (Primary, Secondary And Benign Liver Growths), By Diagnosis (Ultrasound Scans, Confirmatory Needle Biopsy, Endoscopic Ultrasound, Laparoscopy, CT Scan, PET Scan And Magnetic Resonance Imaging (MRI) Scans), By Therapeutics (Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma And Targeted Therapy), By End-User (Pediatrics And Adults) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018-2023)

Asia-Pacific Liver Cancer Therapeutics Market By Type (Primary, Secondary And Benign Liver Growths), By Diagnosis (Ultrasound Scans, Confirmatory Needle Biopsy, Endoscopic Ultrasound, Laparoscopy, CT Scan, PET Scan And Magnetic Resonance Imaging (MRI) Scans), By Therapeutics (Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma And Targeted Therapy), By End-User (Pediatrics And Adults) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018-2023)

ID: 839 | Pages: 145 | April 2018 | Region: Asia Pacific


Asia-Pacific Liver Cancer Therapeutics Market was worth $115.74 million in 2018 and estimated to be growing at a CAGR of 10.05%, to reach $186.83 million by 2023. Recent advances in the treatment for primary liver cancer might deliver some stimulating pointers mainly in the Asian market where sickness and ethnic characteristics demand assessment.

In the Developing regions, such as East and South-East Asia liver cancer is the third most common tumour and the second primary cause of death. Treatment for liver cancer is reliant on numerous factors such as size, type and age of the tumour and whether the cancer has extended outside the liver.

Asia Pacific characterises as the fastest growing liver cancer treatment market owing to the rising geriatric populations. This increasing number of liver cancer cases in the Asian countries involves huge number of drugs for the treatment or prevention of liver cancer and tumours. Further, growing healthcare expenditure and increasing government initiatives are also augmenting the growth of this market. Huge capital investment is a key restraint hindering the growth of the market.

The Asia-Pacific liver cancer therapeutics market is segmented on the basis of type into primary, secondary and benign liver growths. On the basis of therapeutics, the market is bifurcated into hepatocellular carcinoma, Cholangio carcinoma, Hepatoblastoma and targeted therapy. By end-use the market is divided amongst pediatrics and adults. Hepatocellular Carcinoma is the largest segment for therapeutics type due to the high prevalence of this type of liver cancer among people.

Based on geography the market is analysed under various regions namely, China, India, Japan, South Korea and Australia. China is the country in terms of revenue of the market for this region while India and Japan are projected to grow at a high rate in the forecast period.

Some of the key contributors in the industry include Alnylam Pharmaceuticals Inc., ImClone Systems Inc., Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., ArQule Inc., Jennerex Biotherapeutics Inc., Celsion Corp., Bayer Schering Pharma AG, 4SC AG, and Bristol-Myers Squibb Company.

1. Introduction                             

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By Type                     

                             5.1.1 Primary    

                             5.1.2 Secondary             

                             5.1.3 Benign Liver growths         

              5.2 By Therapeutics                     

                             5.2.1 Hepatocellular Carcinoma

                             5.2.2 Cholangio carcinoma        

                             5.2.3 Hepatoblastoma  

                             5.2.4 Targeted Therapy

              5.3 By End-Users                          

                             5.3.1 Pediatrics

                             5.3.2 Adults      

6. Geographical Analysis                                         

              6.3 Asia-Pacific               

                             6.1 Introduction             

                             6.2 China           

                             6.3 India            

                             6.4 Japan           

                             6.5 South Korea             

                             6.6 Australia     

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8. Strategic Analysis                                   

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                    

              9.1 Alnylam Pharmaceuticals Inc.                          

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 ImClone Systems Inc.                          

              9.3 Onyx Pharmaceuticals Inc.                 

              9.4 F. Hoffmann-La Roche Ltd.                

              9.5 Pfizer Inc.                  

              9.6 ArQule Inc.               

              9.7 Jennerex Biotherapeutics Inc.                         

              9.8 Celsion Corp.                          

              9.9 Bayer Schering Pharma AG                

              9.10 4SC AG                    

              9.11 Bristol-Myers Squibb Company                    

10. Competitive Landscape                                     

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11. Expert Opinions                                   

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Asia-Pacific Liver Cancer Diagnostics and Therapeutics Market By Region, From 2018-2023 (USD Million)
  2. Asia-Pacific Liver Cancer Diagnostics and Therapeutics Market By Type, From 2018-2023 (USD Million)
  3. Asia-Pacific Primary Market By Region, From 2018-2023 (USD Million)
  4. Asia-Pacific Secondary Market By Region, From 2018-2023 (USD Million)
  5. Asia-Pacific Benign Liver growths Market By Region, From 2018-2023 (USD Million)
  6. Asia-Pacific Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2018-2023 (USD Million)
  7. Asia-Pacific Hepatocellular Carcinoma Market By Region, From 2018-2023 (USD Million)
  8. Asia-Pacific Cholangio carcinoma Market By Region, From 2018-2023 (USD Million)
  9. Asia-Pacific Hepatoblastoma Market By Region, From 2018-2023 (USD Million)
  10. Asia-Pacific Targeted Therapy Market By Region, From 2018-2023 (USD Million)
  11. Asia-Pacific Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2018-2023 (USD Million)
  12. Asia-Pacific Pediatrics Market By Region, From 2018-2023 (USD Million)
  13. Asia-Pacific Adults Market By Region, From 2018-2023 (USD Million)
  14. China Liver Cancer Diagnostics and Therapeutics Market By Type, From 2018-2023 (USD Million)
  15. China Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2018-2023 (USD Million)
  16. China Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2018-2023 (USD Million)
  17. India Liver Cancer Diagnostics and Therapeutics Market By Type, From 2018-2023 (USD Million)
  18. India Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2018-2023 (USD Million)
  19. India Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2018-2023 (USD Million)
  20. Japan Liver Cancer Diagnostics and Therapeutics Market By Type, From 2018-2023 (USD Million)
  21. Japan Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2018-2023 (USD Million)
  22. Japan Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2018-2023 (USD Million)
  23. South Korea Liver Cancer Diagnostics and Therapeutics Market By Type, From 2018-2023 (USD Million)
  24. South Korea Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2018-2023 (USD Million)
  25. South Korea Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2018-2023 (USD Million)
  26. Australia Liver Cancer Diagnostics and Therapeutics Market By Type, From 2018-2023 (USD Million)
  27. Australia Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2018-2023 (USD Million)
  28. Australia Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2018-2023 (USD Million)
Middle-East & Africa Cardiovascular Therapeutic Drugs By Disease (Arteriosclerosis, Cardiac Arrhythmias, Myocardial Infarction, Acute Coronary Syndrome, Peripheral Artery Disease, Coronary Artery Disease, Hypertensi...
Middle East And Africa Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail...
Latin America Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmaci...
Asia Pacific Clostridium Botulinum Market By Product (botulinum Toxin Type A And Botulinum Toxin Type B), By End User (aesthetic And Therapeutics), By Distribution Channel (hospitals, Clinics And Retail Pharmacies) ...
Europe Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmacies) And...
North America Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmaci...
Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmacies) And By Reg...
The Dental Bone Graft Substitutes Market Is Predicted To Reach USD 664.3 Million With A CAGR Of 9.8% According To Market Data Forecast Report....
Middle East And Africa Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal D...
Latin America Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Reg...
Asia-Pacific Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Rege...
Europe Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Regenerati...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.